"Mr. Tata's investment is a strong affirmation of the quality of the technology that Invictus has developed. We are getting excellent traction from investors, both from India and outside India." said Shiladitya Sengupta, Co-founder, Invictus, and Assistant Professor of Medicine, Harvard Medical School.

Invictus Oncology is engaged in designing anticancer drugs that targets the tumor and also regulates the tumor immune response utilizing a supramolecular technology platform. As per company claims, its lead molecule IO 125 has already been validated in multiple cancer models. The molecule is also poised to get into INDenabling studies to obtain US Food and Drug Administration (US FDA) approval. The approval will act as a green signal to initiate clinical studies. As per company claims, it has already developed a "deep pipeline of molecules," that address a $20Bn market opportunity in the oncology space.

This is Tata’s first investment in Indian biotechnology and pharma startup space that adds to his rapidly expanding portfolio. He has made almost 30 investments over the past 12-18 months. His investment portfolio comprises of many startups, ranging from e-commerce firms to cab aggregators. The corporate titan has previously invested in prominent firms such as Snapdeal, Paytm, Urban Ladder, Bluestone Zivame, CarDekho, Kaaryah, and Ola.

Invictus Oncology is a biopharmaceutical company based in Delhi, India focused on the development of novel therapeutics for cancer treatment.

Read also: 5 Fastmover Startups in India

6 Successful Women Entrepreneurs Who Rock the Indian Startup Scene